CDER’s Woodcock Retiring? Rumors Never Go On Furlough
On day 10 of the federal government shutdown, a Reuters story sparks concern inside and outside the agency that FDA’s drugs center director could soon retire without an obvious successor waiting in the wings; Woodcock fires back with a memo assuring CDER staff she has no plans to leave.
You may also be interested in...
Woodcock's Legacy: CDER Organizational Improvements
In interview with the Pink Sheet, Center for Drug Evaluation and Research director discusses her 30-year career, retirement speculation, and upcoming projects.
CBER Director Midthun Retiring; Legacy Includes Biosimilar Principles, Avastin Withdrawal
While CBER is often perceived to be as much focused on research as it is on application review, Midthun was central to many key policy debates.
Shutdown Week Two: Could Sponsors Find A More Focused FDA?
User-fee supported employees continue to work on pending reviews, and the lack of distractions from other tasks may help sponsors as the shutdown continues.